Tripartite competition on COPD markets.

The business interests in the chronic obstructive pulmonary disease (COPD) therapy is surging up slowly to the market and very competitive by 3 big foreign drug corporations, AstraZeneca, GSK and Boehringer/Pfizer.

COPD is a chronic obstructive respiratory tract disorder with symptoms of cough, breathless and whooping cough, and commonly improved when early treated.

All over the world the...